CRIS Current Research Information System

LONETTI, ANNALISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.477
EU - Europa 6.645
AS - Asia 4.018
AF - Africa 395
SA - Sud America 31
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 4
Totale 18.586
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.419
GB - Regno Unito 2.113
CN - Cina 1.437
SE - Svezia 1.281
VN - Vietnam 1.035
DE - Germania 865
SG - Singapore 819
IT - Italia 760
IN - India 397
RU - Federazione Russa 372
IE - Irlanda 236
FR - Francia 228
ZA - Sudafrica 164
TG - Togo 140
UA - Ucraina 137
EE - Estonia 131
GR - Grecia 117
CH - Svizzera 114
FI - Finlandia 81
IR - Iran 76
JO - Giordania 65
BG - Bulgaria 60
CA - Canada 56
BE - Belgio 41
NG - Nigeria 39
NL - Olanda 36
CI - Costa d'Avorio 32
KR - Corea 30
TR - Turchia 26
HK - Hong Kong 23
JP - Giappone 23
AT - Austria 19
PH - Filippine 18
BR - Brasile 16
SC - Seychelles 16
AU - Australia 14
ID - Indonesia 13
CZ - Repubblica Ceca 11
PL - Polonia 11
TW - Taiwan 11
LB - Libano 9
ES - Italia 8
UZ - Uzbekistan 8
CL - Cile 7
MY - Malesia 7
PT - Portogallo 7
PK - Pakistan 6
PE - Perù 5
IQ - Iraq 4
RO - Romania 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BD - Bangladesh 3
EG - Egitto 3
KZ - Kazakistan 3
LT - Lituania 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
EU - Europa 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MX - Messico 1
NO - Norvegia 1
PA - Panama 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UY - Uruguay 1
Totale 18.586
Salva come PNG Salva come JPEG
Città #
Southend 1.987
Chandler 802
Fairfield 734
Singapore 693
Dong Ket 625
Houston 515
Ashburn 507
Wilmington 408
Princeton 361
Woodbridge 354
Ann Arbor 343
Seattle 321
Santa Clara 313
Dublin 236
Cambridge 226
Boardman 218
Nanjing 193
Westminster 182
Bologna 178
Beijing 163
Padova 155
Lomé 140
Medford 122
Bern 103
Redmond 101
Shenyang 93
Jinan 92
Berlin 91
New York 86
Helsinki 81
Saint Petersburg 79
Hebei 67
Amman 65
Sofia 60
Changsha 57
Bremen 54
Falls Church 52
Nanchang 51
Florence 49
Tianjin 46
San Diego 43
Jacksonville 42
Turin 41
Brussels 40
Abeokuta 39
Zhengzhou 39
Milan 38
Guangzhou 37
Frankfurt am Main 36
Los Angeles 33
Abidjan 32
Norwalk 32
Jiaxing 30
Ningbo 30
Mülheim 29
Hangzhou 26
Redwood City 26
Shanghai 26
Taiyuan 26
Toronto 26
Haikou 25
Grafing 23
Hong Kong 19
Kunming 19
Athens 18
Davao City 18
Istanbul 18
North York 18
Tehran 17
Fuzhou 16
Falkenstein 15
Leawood 15
Mahé 15
Dearborn 14
Olalla 14
Taizhou 13
Vienna 13
Yubileyny 13
Andover 12
Bühl 12
Rome 12
Zanjan 12
Amsterdam 11
Des Moines 11
Jakarta 11
London 11
Halethorpe 10
Hefei 10
Lanzhou 10
Nuremberg 10
Orange 10
Paris 10
Phoenix 10
Qingdao 10
Xi'an 10
Chengdu 9
San Francisco 9
Frankfurt Am Main 8
Moscow 8
Mountain View 8
Totale 12.201
Salva come PNG Salva come JPEG
Nome #
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 279
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 256
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 239
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 230
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 221
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 208
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 200
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. 192
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 192
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 187
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 171
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 170
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 164
COMBINING DOT1L INHIBITOR EPZ-5676 WITH SORAFENIB TO TREAT MLL-REARRANGED (MLL-R) PEDIATRIC ACUTE MYELOID LEUKEAMIA (AML) 160
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 157
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 157
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 156
Therapeutic targeting of CK2 in acute and chronic leukemias. 155
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 149
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 149
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 149
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 148
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. 147
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. 147
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 142
Improving nelarabine efficacy in T-cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. 141
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 141
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 139
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 136
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 135
Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. 133
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 133
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 132
COMBINAZIONE DI EPZ-5676 E SORAFENIB COME NUOVA STRATEGIA TERAPEUTICA PER IL TRATTAMENTO DELLE LEUCEMIE ACUTE MIELOIDI PEDIATRICHE 132
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 132
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 131
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 130
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 130
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 130
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 129
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 129
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 128
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 127
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 127
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 127
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 126
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 125
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 125
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. 124
Use of deep whole transcriptome sequencing in Philadelphia-positive acute lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant gene expression and alternative splicing profiles associated with disease progression. 124
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 124
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 123
null 122
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 122
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 122
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 122
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 119
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 119
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 119
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 118
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 114
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 114
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 113
Therapeutic targeting of polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblstic leukemia. 112
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 111
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. 111
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 111
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 110
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients 109
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the pro-apoptotic NF-κB. 109
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 108
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia 108
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 107
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 105
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 105
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 105
Successes and Challenges for Diagnosis and Therapy of Acute Leukemia 105
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 105
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 104
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 103
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 103
null 103
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 103
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) 102
Targeting Hedgehog pathway in pediatric acute myeloid leukemia: challenges and opportunities 101
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 100
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 99
Single nucleotide polymorphisms as genomic markers for high-throughput pharmacogenomic studies 98
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 98
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. 98
Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients 98
Inhibition of methyltransferase dot1l sensitizes to sorafenib treatment aml cells irrespective of mll-rearrangements: A novel therapeutic strategy for pediatric aml 98
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 97
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 97
c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells 97
The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors. 97
null 95
First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, “Deep” and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. 95
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. 95
A novel DAG-dependent mechanism links PKCɑ and Cyclin B1 regulating cell cycle progression 93
Totale 13.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.822
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.822
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.293 0 0 0 0 0 0 0 0 572 246 216 259
2020/20212.507 437 132 94 24 70 68 35 172 239 85 107 1.044
2021/20223.696 497 78 265 302 364 242 71 221 177 314 566 599
2022/20233.627 430 629 202 483 236 271 134 182 528 62 279 191
2023/2024955 47 163 55 83 64 199 41 48 44 48 82 81
2024/20252.366 166 513 305 246 588 193 247 104 4 0 0 0
Totale 19.078